Strides Delivers a strong Q1 FY 2026 with Rs.11 197 million Revenue Rs. 2 181 million EBITDA and Rs. 1 140 million Operational PAT.
29-जुलाई-2025
डाउनलोड पीडीएफ़
Strides Pharma
Strides Delivers a strong Q1 FY 2026 with Rs.11 197 million Revenue Rs. 2 181 million EBITDA and Rs. 1 140 million Operational PAT.